Making Oligonucleotides Better Biopharmaceuticals by Steric Protection

通过空间保护使寡核苷酸成为更好的生物制药

• 批准号: 10259829
• 负责人: Ke Zhang
• 金额: $ 31.15万
• 依托单位: NORTHEASTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259829
• 关键词: Acute; Address; Animals; Antibodies; Antisense DNA; Benign; Binding; Biodistribution; Biological; Biological Products; Blood Circulation; Blood Coagulation Disorders; Bypass; Catalytic RNA; Cations; Cells; Characteristics; Chemical Structure; Chemicals; Chronic; Complementary DNA; Complex; Congestive; DNA; DNA Binding; DNA Probes; DNA Sequence; Data; Deoxyribonucleases; Development; Disease; Drug resistance; Electrostatics; Environment; Enzyme Stability; Exhibits; Face; Gene Therapy Agent; Genes; Genetic; Genetic Diseases; Goals; Half-Life; Immune response; Immune system; Immunization; In Vitro; Insulin; Intracellular Transport; Investigation; Kidney; Kinetics; Liposomes; Liver; Malignant Neoplasms; MicroRNAs; Modality; Modeling; Modification; Molecular; Neurodegenerative Disorders; Nucleic Acids; Oligonucleotides; Outcome Study; Pattern; Pattern recognition receptor; Peptides; Permeability; Pharmaceutical Preparations; Polymers; Property; Proteins; Reticuloendothelial System; Safety; Serum; Serum Proteins; Side; Small Interfering RNA; Specificity; Structure; System; TLR9 gene; Therapeutic; Therapeutic Agents; Thermodynamics; Thrombin; Toxic effect; Vertebral column; Work; aptamer; base; biological systems; biomaterial compatibility; cancer cell; density; design; efficacy study; ethylene glycol; gene therapy; gene therapy clinical trial; immunogenic; immunogenicity; improved; in vivo; insight; interest; knock-down; mouse model; nanoparticle; novel; nuclease; nucleic acid delivery; pathogen; pharmacokinetics and pharmacodynamics; preservation; prevent; protein expression; refractory cancer; side effect; single molecule; stem; tumor; uptake

Project Summary/Abstract Significant interests exist for using oligonucleotides as therapeutic agents, which face several biopharmaceutical difficulties, including stability and delivery issues, and sequence- and/or chemical structure-specific, non-hybridization activities, such as coagulopathies and stimulation of the immune system. These difficulties have been in part overcome by chemical modification of the oligonucleotide backbone or by using delivery systems (oftentimes polycationic structures), which enhance nuclease stability and improve delivery efficiency. However, these approaches either give rise to new challenges (e.g. toxicity and immunogenicity), or cannot adequately address all of the negative aspects. Therefore, a system that can improve nuclease stability, preserve target-binding capability, minimize all off-target effects, and improve biodistribution is still very much sought after. Our preliminary studies have demonstrated that “compaction” of DNA can be achieved by inserting it into a high-density brush polymer environment, which enables the DNA to bind selectively to a complementary DNA strand, while access by various proteins is limited. The binding of DNA with proteins such as nucleases, toll-like receptor 9, and thrombin is generally the first step to non-hybridization side effects. Therefore, the brush polymer- DNA conjugates should bypass many of the side effects of oligonucleotides and has the potential to be applied to essentially all forms of oligonucleotides, i.e. antisense DNA, siRNA, microRNA, aptamers, ribozymes, etc., to improve their biopharmaceutical characteristics. The outcome of this study would be a new class of biocompatible and non-immunostimulatory oligonucleotide-based gene therapy agents, and a fundamental understanding of how its molecular parameters can impact its in vivo and in vitro properties.

项目总结/摘要 对于使用寡核苷酸作为治疗剂存在显著的兴趣，其面临若干挑战。 生物制药困难，包括稳定性和递送问题，以及序列和/或化学 结构特异性、非杂交活性，如凝血病和免疫刺激 系统这些困难已经通过寡核苷酸的化学修饰部分克服 骨架或通过使用递送系统（通常是聚阳离子结构），其增强核酸酶活性。 提高了输送效率。然而，这些方法要么带来新的挑战， (e.g.毒性和免疫原性），或者不能充分解决所有的负面方面。因此 本发明提供了一种系统，其可以改善核酸酶稳定性、保持靶结合能力、最小化所有脱靶 效果和改善生物分布仍然是非常受欢迎的。我们的初步研究表明 证明了DNA的“压缩”可以通过将其插入高密度刷状聚合物中来实现 环境，这使得DNA能够选择性地结合到互补DNA链，同时访问 受到各种蛋白质的限制。DNA与蛋白质如核酸酶，toll样受体9， 而凝血酶一般是第一步产生非杂交副作用。因此，刷状聚合物- DNA缀合物应该绕过寡核苷酸的许多副作用，并有可能被用于治疗癌症。 应用于基本上所有形式的寡核苷酸，即反义DNA、siRNA、微小RNA、适体， 核酶等，以改善其生物制药特性。这项研究的结果将是一个 一类新的生物相容性和非免疫刺激性的基于阿托伐他汀的基因治疗剂，和 基本了解其分子参数如何影响其在体内和体外 特性.